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Background and Purpose The Type 1 Diabetes Genetics Consortium (T1DGC) is an
international project whose primary aims are to: (a) discover genes that modify type
1 diabetes risk; and (b) expand upon the existing genetic resources for type 1
diabetes research. The initial goal was to collect 2500 affected sibling pair (ASP)
families worldwide.
Methods T1DGC was organized into four regional networks (Asia-Pacific, Europe,
North America, and the United Kingdom) and a Coordinating Center. A Steering
Committee, with representatives from each network, the Coordinating Center, and
the funding organizations, was responsible for T1DGC operations. The Coordinating
Center, with regional network representatives, developed study documents and data
systems. Each network established laboratories for: DNA extraction and cell line
production; human leukocyte antigen genotyping; and autoantibody measurement.
Samples were tracked from the point of collection, processed at network laboratories
and stored for deposit at National Institute for Diabetes and Digestive and Kidney
Diseases (NIDDK) Central Repositories. Phenotypic data were collected and entered
into the study database maintained by the Coordinating Center.
Results T1DGC achieved its original ASP recruitment goal. In response to research
design changes, the T1DGC infrastructure also recruited trios, cases, and controls.
Results of genetic analyses have identified many novel regions that affect
susceptibility to type 1 diabetes. T1DGC created a resource of data and samples
that is accessible to the research community.
Limitations Participation in T1DGC was declined by some countries due to study
requirements for the processing of samples at network laboratories and/or final
deposition of samples in NIDDK Central Repositories. Re-contact of participants was
not included in informed consent templates, preventing collection of additional
samples for functional studies.
Conclusions T1DGC implemented a distributed, regional network structure to
reach ASP recruitment targets. The infrastructure proved robust and flexible enough
to accommodate additional recruitment. T1DGC has established significant
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Introduction
The importance of studying diverse groups of
individuals and the need for increased sample
sizes to answer specific disease questions have led
to the conduct of international trials and consortia
in the past decade [1–16]. While some publications
regarding the challenges faced in conducting an
international study are available, there is the need
for more published information to define potential
issues and solutions.
To pool data obtained from such efforts, it is
criticaltostandardizethecollectionproceduresacross
all sitesworldwide.This may prove to be a formidable
task,withavarietyofissuesnotfullyappreciatedfrom
the outset of such a project. The addition of sites
worldwide adds complexity and considerable time to
the planning and implementation processes.
The Type 1 Diabetes Genetics Consortium
(T1DGC) is an international project sponsored by
the National Institute for Diabetes and Digestive and
Kidney Diseases (NIDDK) and the Juvenile Diabetes
Research Foundation (JDRF) whose primary aims are
to: (a) discover genes that modify the risk of type 1
diabetes; and (b) expand upon the existing genetic
resources for type 1 diabetes. The initial Consortium
goal was to collect 2500 affected sibling pair (ASP)
families throughout the world. These families would
provide medical history information as well as
samples for immortalized cell lines, DNA, plasma,
and serum. All samples eventually will be deposited
in the NIDDK Central Repositories and made
available to the scientific community.
Methods
Study organization
Defining the study organization is an important first
step in developing the necessary infrastructure to
undertake such a project. The T1DGC has its Project
Office at NIDDK and includes a Steering Committee,
an External Evaluation Committee (EEC), Network
Centers, Network Laboratories, StandingCommittees
and a Coordinating Center as well as liaisons and
program observers from various National Institutes of
Health (NIH) agencies and studies. Figure 1 illustrates
the size and complexity of this project.
Steering Committee
The T1DGC Steering Committee was responsible for
the overall T1DGC study. Steering Committee inves-
tigators participated in the design and execution of
the project and collectively approved decisions for the
Coordinating Center to execute. Members included
representatives from each regional Network, the
Coordinating Center, and program staff from the
sponsoring organizations. Decisions were made by a
majorityvoteofaquorumofthecommitteemembers.
TheSteeringCommitteemetbyconferencecalloncea
month and in face-to-face meetings twice per year.
External Evaluation Committee
NIDDK established an EEC that was responsible for
ongoing evaluation of the study design and
monitoring the progress of the T1DGC. EEC
members included investigators with relevant
scientific expertise, but who were not the members
of the Consortium.
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To facilitate participant recruitment, the
Consortium was organized into four regional
Networks: Asia-Pacific, European, North American,
and United Kingdom. The Asia-Pacific Network
Center was located at the Walter and Eliza Hall
Institute of Medical Research in Melbourne,
Australia, and had 20 clinics. The European
Network Center was located at the Hagedorn
Research Institute (formerly Steno Diabetes
Center) in Gentofte, Denmark, with 84 clinics.
The North American Network Center was located at
Benaroya Research Institute in Seattle, WA, USA,
and had 62 clinics. The United Kingdom Network
Center was located at the University of Cambridge
and included 48 clinics. A total of 214 clinics in 34
countries participated in recruitment for T1DGC.
Each network was responsible for coordinating
and monitoring all the clinic activities within the
region. Each of the four networks established a
network infrastructure, developing the Network
Center and regional organizations through contacts
with investigators and clinicians with ASP families to
contribute to the collection. A Network Coordinator
was appointed for each region. Each network was
given flexibility to develop its region as deemed
necessary for the overall success of the Consortium.
To identify participating clinics, network meet-
ings were held to outline the T1DGC collection
requirements (i.e., data and samples required for
inclusion) and to determine investigator interest
and feasibility of participation. Following such
meetings, the regional Network Coordinator
would obtain detailed clinic information, such as
the estimated number of available families, staff
contacts, and local or national issues that might
prevent participation in the Consortium.
Eachregional Network Centerwas responsible for
coordinatingandmonitoring studyactivitieswithin
the region. Network Centers worked with investiga-
tors at participating clinics to prepare materials for
submission to Institutional Review Boards (IRBs)
and Ethical Committees (ECs). Network Centers
performed all data entry and maintained contin-
uous interaction with network clinics and labora-
tories as well as the Coordinating Center.
Laboratories
Each of the four regional networks established three
types of laboratories to perform activities integral to
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Figure 1 T1DGC organization chart.
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establish cell lines and extract DNA for genotyping
projects; an Autoantibody and Storage Laboratory
for measurement of autoantibodies and temporary
storage of serum and plasma samples; and a Human
Leukocyte Antigen (HLA) Genotyping Laboratory
for HLA characterization. A quality assurance (QA)
plan was established and implemented; assays were
standardized across each type of laboratory.
Internal quality control (QC) data or any existing
comparisons between laboratories were submitted
to and reviewed at the Coordinating Center. All of
the T1DGC laboratories participated in annual
comparisons and/or QC exercises.
Other laboratories were selected for specific
genotyping projects. These included the Center for
Inherited Disease Research (CIDR) (Johns Hopkins
University, Baltimore, MD, USA; genotyping for
linkage), The Wellcome Trust Sanger Institute
(Hinxton, UK; fine mapping of the major histocom-
patibility complex (MHC) region), and The Broad
Institute Center for Genotyping and Analysis
(Cambridge, MA, USA; evaluation of candidate
genes for type 1 diabetes). Data from these projects
were sent to the Coordinating Center for additional
QC checks prior to data distribution and analyses.
Coordinating Center
The T1DGC Coordinating Center (Division of
Public Health Sciences, Wake Forest University
Health Sciences, Winston-Salem, NC, USA) mon-
itored and supported data collection activities
within the four Network Centers. Since the regional
Network Centers were charged with coordinating
and monitoring all clinic activities within the
region, the Coordinating Center interacted only
with the Network Centers and not with individual
clinics in a region.
The Coordinating Center established and main-
tained QA standards for all activities of the study
and worked with the Network Centers and labora-
tories to implement decisions made by the T1DGC
Steering Committee. In addition, the Coordinating
Center was responsible for fiscal administration of
the project.
Three specialized teams were established, each
focusing on specific aspects of the study (i.e.,
Operations, Systems, and Statistics). The
Operations Team, in collaboration with regional
representatives, developed all study materials,
including: a template for informed consent; the
protocol; a manual of operations; and data collec-
tion forms for ASP, trio, and case–control collec-
tions. Revisions to each of these documents were
implemented as needed. Included in the manual of
operations were figures to provide visual references
for key aspects of the data and sample collection
(Figures 2 and 3). The Systems Team was respon-
sible for data flow, architecture, and security. This
team developed and finalized two study websites
(T1DGC public site (www.t1dgc.org) and an inter-
nal T1DGC data entry site for certified Network
Center and laboratory personnel) as well as other
fully web-based applications, including a specimen
tracking system and a HLA genotyping laboratory
system. The Statistics Team was responsible for data
management, QA/QC, data set creation and dis-
tribution, and initial analyses.
Standing Committees and Working Groups
Ten standing committees were established to
implement Consortium activities and provide
opportunities for T1DGC members to participate.
Each committee included representatives from
the four regional networks, the Coordinating
Center, and the sponsoring organizations. T1DGC
committees included: Access; Bioinformatics;
Ethical, Legal, and Social Implications (ELSI);
Network Coordinators; Phenotyping/Recruitment
(including eligibility review and approval);
Publications and Presentations; and four QC
Committees (Autoantibody, DNA Repository, HLA
Genotyping, and Forms Data). Monthly calls with
each of the QC Committees were used to review QC
reports and to discuss laboratory-specific issues.
Other committees scheduled calls as required to
deal with specific study issues. Face-to-face meet-
ings of all T1DGC committees were held annually.
In addition to the Standing Committees, T1DGC
established two Working Groups (MHC and Rapid
Response) to analyze data associated with two
genotyping projects. Each group comprised experts
in the specific regions that were genotyped.
Training, certification, and pilot studies
Cultural and language differences made study-
wide, central training sessions difficult. T1DGC
used a ‘train the trainer’ model where Network
Center staff members were trained at the Network
Center by Coordinating Center staff. The
Network Coordinator, in turn, was responsible for
subsequent training of clinic staff, either centrally
or individually. This model enabled networks to
initiate data collection on a staggered timetable.
Following training, each participating clinic was
required to conduct a pilot study before initiating
T1DGC data collection. Data were reviewed by a
Coordinating Center Project Manager who certified
or provided final approval for the clinic to begin
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Clinical Trials 2010; 7: S5–S32 http://ctj.sagepub.comT1DGC participant recruitment. All data collection
forms were data entered at the Network Center by
staff trained and certified in the data entry system.
Quality control
The Coordinating Center established QA proce-
dures and QC metrics for all Consortium activities.
These activities included the data collection forms
entry [17], sample assays for the Network
Laboratories [18–20], and any genotyping per-
formed on the samples [21,22]. T1DGC samples
were deposited at the NIDDK Central Repositories
and the Coordinating Center worked with NIH staff
to assure that samples received were of high
quality.
Results and lessons learned
Organization
The T1DGC Steering Committee was responsible
for the overall T1DGC study and members actively
participated in the design and execution of the
project. From the outset, T1DGC decided that a
distributed organization of regional networks was
necessary to complete a worldwide recruitment of
2500 ASP families. Four regional Networks (in Asia-
Pacific, Europe, North America, and the United
Kingdom) were organized, with the aim to ensure
standardized collection procedures across all sites
worldwide. This proved to be a formidable task,
with a variety of issues not fully identified from the
outset of such a project.
Eligibility form
Informed consent 
signed (by each
participant)
Interview:  exam form 
(not applicable for 
controls)
Send completed 
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Network Center 
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Forms entered at 
Regional
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Data transmitted to
Coordinating Center
Blood collection and processing 
Exit
interview
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Cell line,
cell pack and
QC samples
Receipt and 
inventory to 
Coordinating Center
Autoantibody,
storage, and QC 
samples
Ship to Autoantibody
and Storage Laboratory
monthly
Receipt and 
values to 
Coordinating Center
Assign participant IDs  
on consent summary form (not
used for case/control) 
Send letter of 
introduction
(optional)
NO YES
Assign family ID (case/control ID) 
Assess eligibility of other family members
(ASP families only) 
YES
Schedule exam for eligible members (individuals)
Ship to DNA 
Repository daily
NO
Assess required family members 
eligibility (individual eligibility for 
case/control)
North American 
trio pre-eligibility 
form
NO
Figure 2 T1DGC data and sample collection flow.
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consortium was the development of the T1DGC
Consortium Agreement (Appendix 1) that incenti-
vized investigator participation. This agreement
clearly defined the activities of the Consortium and
member rights and responsibilities. The agreement
acknowledged contributing investigators and expli-
citly respected their research prerogatives. It also
outlined a timeline for making T1DGC resources
available to contributing investigators, to T1DGC
members, and to the broader research community.
Recruitment
To facilitate worldwide recruitment, each network
was given flexibility to develop its own Network
Centerandregionalorganizationtomeettheoverall
participant recruitment goals. While this resulted in
very different approaches across the four networks,
it led to the overall success of Consortium recruit-
ment, as each network could deal with the unique
social, cultural, ethical, and legal issues of different
countries. This flexible approach proved to be an
effective and successful strategy.
Network meetings were a key factor in facilitat-
ing interaction among participating investigators
within networks. For example, the initial network
meetings outlined the T1DGC collection require-
ments and determined investigator interest and
feasibility of participating. Subsequent network
meetings, generally on an annual basis, provided
updatesonthestatusofrecruitment,activitiesofthe
Consortium, and new developments in type 1
diabetes genetics. At some subsequent network
meetings, additional training was provided for
areas of the study that required more emphasis and
training for new aspects of the study was conducted.
FILLING
PRIORITY: 1
TYPE 1 DIABETES GENETICS CONSORTIUM BLOOD FLOW CHART
4
CENTRIFUGE
4.9-mL PURPLE (EDTA plasma)
Autoantibody and Sample Storage Laboratory
Stand at
ROOM
TEMPERATURE
chill,
centrifuge,
or aliquot
Cell Line
GREEN-top tube
7.5-mLGREEN
(Sodium heparin)
7.5-mL RED (serum)
FREEZE
ICE 30–60 min STAND 30–60 min
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Serum storage
2-mL cryovials
0.5 mL each
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Plasma storage
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Ship MONTHLY
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DO NOT
Ship DAILY at
ambient temperature
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for
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DNA
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2 3
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Figure 3 T1DGC blood collection chart.
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with the delegation of other activities contributed
to the smooth running of the Consortium and the
success of recruitment. Initially, T1DGC collected
only ASP families. Later, on the recommendation of
the Steering Committee and the approval of the
EEC, T1DGC included the recruitment of trios
(father, mother, and a child with type 1 diabetes),
as well as cases (with type 1 diabetes) and controls
(no history of type 1 diabetes) from populations
with a low prevalence of the disease. In Asia-Pacific,
these included individuals from India, Thailand,
Malaysia, Philippines, and Singapore. In Europe,
Cameroon was included to provide trios, cases, and
controls. In North America, Mexican-American,
and African-American individuals were included.
Table 1 provides a summary of the T1DGC recruit-
ment and basic demographics for eligible partici-
pants as of July 4, 2009. Recruitment and data
cleaning are ongoing.
The protocol, manual of operations, and data
collection forms were developed centrally at the
Coordinating Center, with input from network
representatives. All study documents were made
available on the T1DGC website (www.t1dgc.org).
T1DGC standardized supplies and services
worldwide by establishing central billing
accounts and using vendors that would permit
clinics to order from a common catalog
of supplies. Central billing accounts were created
for: blood collection supplies to be used in the
clinics (Sarstedt, Inc.); fetal bovine serum to be used
in establishing cell lines in the Network DNA
Repositories (Invitrogen, Inc.); and couriers to
ship specimens from the clinics to laboratories
and from DNA Repositories to genotyping facilities
(Federal Express and World Courier). Locating
vendors and establishing the master accounts
took considerable time and effort, so the decision
to pursue this type of arrangement should be made
as early as possible in the planning process to avoid
delays in data collection. For instance, when
T1DGC realized that there could not be a single
worldwide courier for shipping samples, an account
with Federal Express was used for shipments within
North America and another account with World
Courier was used for shipments in the Asia-Pacific
and European Networks. In the United Kingdom,
no courier master account was required as the
postal system was used for shipping cell line
samples to Cambridge and a local van courier for
frozen shipments to the laboratory in Bristol.
Regulatory issues
Everyinstitutionengagedinhumansubjectsresearch
supported or conducted by the US Department of
Health and Human Services (DHHS) must obtain an
assurance of compliance approved by the Office for
Human Research Protections (OHRP). Some interna-
tional institutions did not have an active Federal
Wide Assurance (FWA) number and this was a
primary cause of delayed recruitment in clinics.
Some networks overcame this issue by using an
Unaffiliated Investigator Agreement, where one
institution agreed to serve as an umbrella for other
collection sites. Clinic sites also were encouraged to
register their IRB and apply for an FWA number
online at the OHRP website. As with other studies,
obtainingIRB or ECapprovalwas the major sourceof
delay in initiating recruitment, as each IRB or EChad
its own set of requirements.
The T1DGC ELSI Committee dealt with the large
number of issues related to informed consent [23].
This group finalized a set of templates (self consent,
parental consent, teenage assent, and child assent)
that was agreed to by all networks. Templates could
be modified to comply with local IRB or EC
requirements, as long as a defined set of specific
elements required for the T1DGC collection were
included in the final approved version.
Dealing with informed consent language is a
time-consuming task in any study, but was parti-
cularly so in T1DGC, given the diverse require-
ments necessary to satisfy hundreds of IRBs or ECs.
Particular to a genetics study, T1DGC had to be
sensitive to specific cultural issues about the
collection of genetic material and to reassure
investigators from countries who felt that genetics
collection was primarily an exploitive activity.
T1DGC added language to the consent templates
to specifically state that the Consortium would not
claim any intellectual property rights, sell the DNA,
or develop any commercial products.
In North America, several US IRBs required the
T1DGC to apply for and obtain a Certificate of
Confidentiality. To ensure compliance with the
Health and Insurance Portability and
Accountability Act (HIPAA), the Coordinating
Center developed and executed Data Use
Agreements for transfer of data between each of
the Network Centers and the Coordinating Center.
Study communication
In general, T1DGC committees had monthly con-
ference calls throughout the study. Email was the
primary means of communication between the
Coordinating Center and the Network Centers,
especially in the intervals between conference
calls. Face-to-face meetings of committee members
occurred annually.
T1DGC greatly benefited from web-based com-
munications. There were two study websites: a
public site with login access for Consortium
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Asia-Pacific European North American United Kingdom Overall
Affected sibling pair families
Number completed families 324 1215 1153 163 2855
Gender (percent)
Male 46.6 48.6 49.3 45.2 48.4
Female 53.4 51.4 50.7 54.8 51.6
Race (percent)
American Indian/Alaskan Native 0.0 0.0 0.2 0.0 0.1
Asian 6.7 0.0 0.7 1.3 1.2
Native Hawaiian or other Pacific Islander 1.3 0.0 0.2 0.0 0.2
Black or African American 1.6 0.2 2.2 0.7 1.2
White or Caucasian 90.3 99.8 96.7 97.9 97.3
For affected participants (mean SD
a)
Age at ascertainment (proband) 21.7 12.4 25.6 13.3 21.3 12.9 16.7 6.4 22.9 13.0
Age at diagnosis (proband) 8.0 6.3 9.7 7.1 7.6 5.7 6.2 4.3 8.5 6.4
Age at ascertainment (affected siblings) 20.0 12.2 24.1 13.2 19.7 13.0 14.2 5.8 21.3 13.0
Age at diagnosis (affected siblings) 12.8 8.4 14.8 9.0 11.5 7.9 8.8 4.4 12.9 8.5
Trio families
Number completed families 269 11 192 N/A
b
Gender (percent)
Male 48.5 60.0 47.5 N/A 48.2
Female 51.5 40.0 52.5 N/A 51.8
Race (percent)
American Indian/Alaskan Native 0.0 0.0 0.0 N/A 0.0
Asian 100.0 0.0 0.0 N/A 57.5
Native Hawaiian or other Pacific Islander 0.0 0.0 0.0 N/A 0.0
Black or African American 0.0 100 48.0 N/A 21.2
White or Caucasian 0.0 0.0 52.0 N/A 21.3
For affected participant (mean SD)
Age at ascertainment (proband) 16.5 7.4 14.7 4.8 11.1 4.6 N/A 14.3 6.9
Age at diagnosis (proband) 10.2 5.4 11.3 4.2 7.2 4.0 N/A 9.0 5.0
Cases
Number completed 4 0 390 N/A 394
Gender (percent)
Male 100.0 0.0 46.0 N/A 46.5
Female 0.0 0.0 54.0 N/A 53.5
Race (percent)
American Indian/Alaskan Native 0.0 0.0 0.0 N/A 0.0
Asian 100.0 0.0 0.0 N/A 1.0
Native Hawaiian or other Pacific Islander 0.0 0.0 0.0 N/A 0.0
Black or African American 0.0 0.0 77.7 N/A 76.9
White or Caucasian 0.0 0.0 22.3 N/A 22.1
Age at ascertainment (mean SD) 21.8 3.9 0.0 14.8 7.7 N/A 14.9 7.7
Age at diagnosis (mean SD) 14.2 2.9 0.0 8.9 5.4 N/A 8.9 5.5
Controls
Number completed 2 0 527 N/A 529
Gender
Male 100.0 0.0 23.6 N/A 23.9
Female 0.0 0.0 76.4 N/A 76.1
Race
American Indian/Alaskan Native 0.0 0.0 0.0 N/A 0.0
Asian 100.0 0.0 0.0 N/A 0.4
Native Hawaiian or other Pacific Islander 0.0 0.0 0.0 N/A 0.0
Black or African American 0.0 0.0 81.0 N/A 80.7
White or Caucasian 0.0 0.0 19.0 N/A 18.9
Age at ascertainment (mean SD) 23.0 1.4 0.0 32.8 12.8 N/A 32.8 12.8
aSD – standard deviation.
bN/A – not applicable.
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for input and access to all study data that was
accessible only to specified study personnel. Since
data were available to all Network Coordinators,
real-time monitoring of recruitment was possible
and was used as an incentive to spur recruitment
efforts. Network laboratories used the data entry
site to report their results to the Coordinating
Center. The T1DGC also developed a web-based
application for the HLA Genotyping Laboratories to
report their results [20].
The T1DGC website (www.t1dgc.org) was used
to communicate with the general T1DGC member-
ship and the public. Specific pages of the website
were used for communications with different
T1DGC committees and working groups, including
the Steering Committee. The Consortium
Agreement, access policies, and copies of data
collection forms were all available on the T1DGC
website.
Quality control
The T1DGC Steering Committee appreciated that
having standardized assays and/or methods across
network laboratories would be critical for the
success of the study. The T1DGC study data are
primarily of two types: medical history information
recorded on data collection forms and laboratory
results. Since there were three types of laboratories
within each network, the central QC Committee
was comprised of four subcommittees: (1) Forms
Data; (2) DNA Repositories; (3) Autoantibody
Laboratories; and (4) HLA Genotyping Laboratories.
The QC Committee and the Coordinating
Center developed QA procedures, including a
central manual, for use in all networks. To imple-
ment QA, the QC Committee reviewed internal QC
data or any existing comparison data among the
network laboratories and also conducted annual
comparisons of laboratories worldwide. This
ensured consistency and allowed the study to
monitor for assay drift.
The QC Committee conducted site visits to each
regional Network Center and Network Laboratory
to monitor adherence to the protocol under normal
operating conditions. Site visits also were used to
identify and resolve any data collection issues at
individual clinics and/or any questions about
sample shipments, handling, and analysis proce-
dures at the laboratories. It proved challenging, but
possible, to train and to impose rigorous QA
procedures across networks. Again, insistence on
uniform standards, with flexibility on specific
details, was critical to implementing the established
QA standards.
Access
One of the main goals of the T1DGC was to share
its data, samples, and resources with the broader
research community. This goal was prominently
stated in the Consortium Agreement and was
implemented by the Access Committee. The
T1DGC access policy is available on the website
(www.t1dgc.org) and included as Appendix 2.
Importantly, there is a prominent banner on the
website that highlights data and sample availabil-
ity. There is also a list of all investigators who have
been provided access to T1DGC resources (samples
and/or data).
The T1DGC is depositing samples and data in all
three NIDDK Central Repositories (Biosample,
Genetics, and Data). The Central Repositories
were established to expand the utility of NIDDK-
supported studies by allowing the research com-
munity to continue to access these materials
beyond the end of the study.
T1DGC conducted training workshops for HLA
genotyping and for bioinformatics in a conscious
effort to export technology, providing hands-on
opportunities for T1DGC members. Since real
T1DGC samples and data were used, these work-
shops also highlighted the availability of the
resources.
Genotyping
All genotyping of T1DGC samples was performed
centrally, although different laboratories were used
for different aspects of the study. The Coordinating
Center worked with the Network DNA Repositories
to ship samples to the selected facility. Genotype
data were returned to the Coordinating Center,
where the Statistics Team was responsible for
performing additional QC checks and initial ana-
lyses. The results of all analyses undertaken by
T1DGC have been made available to the T1DGC
membershipandannouncedontheT1DGCwebsite.
The initial T1DGC activity was a joint analysis of
three historical genome-scan data sets (UK, US, and
Scandinavia), combined with data from 254
T1DGC ASP families that had been genotyped by
CIDR. These results were published as an Original
Article in Diabetes [24]. This was followed by
genotyping all T1DGC-collected ASP families,
with genotyping performed by CIDR and the results
published in Diabetes [25].
The T1DGC subsequently genotyped  10,000
samples at The Wellcome Trust Sanger Institute to
generate a data set of single nucleotide polymorph-
isms (SNPs) and microsatellites within the 4 Mb
classical MHC region. This information was
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performed in the T1DGC HLA Genotyping
Laboratories. This comprehensive, unique data
resource was made available to multiple analytic
working groups. Their results are presented in a
supplement of Diabetes, Obesity and Metabolism [26].
The same  10,000 DNA samples have been used
to investigate previously reported candidate genes
for type 1 diabetes, to confirm the most highly
associated SNPs reported by the Wellcome Trust
Case Control Consortium (WTCCC) [27], to study
recently reported genes that contribute to risk of
type 2 diabetes and are implicated in b-cell func-
tion, and to interrogate recently reported genes
from genome-wide association studies (GWAS) of
other autoimmune diseases. Genotyping for these
projects was performed at The Broad Institute and
the results are presented in a supplement of Genes
and Immunity [28].
The T1DGC has completed Stage 1 of a GWAS,
using  500,000 SNPs in 4000 cases from the JDRF/
Wellcome Trust British case collection and 2500
controls from the British 1958 Birth Cohort (B58C).
These results were combined with existing data
from the WTCCC study of type 1 diabetes [27] and
from the Genetics of Kidneys in Diabetes (GoKinD)
Study [29]. Genotyping was by contract to Illumina
and Professor David Clayton (University of
Cambridge, UK) led the analysis. The results have
been published in Nature Genetics [30]. Follow-up
studies to the GWAS Stage 1 currently are underway
and are utilizing T1DGC samples.
Limitations
The original T1DGC research plan for a linkage
study guided the decision to collect ASP families.
From the outset, the Steering Committee recog-
nized that the rapid development of genotyping
technologies would make it necessary to anticipate
modifications in the research design. Indeed, one
rationale for establishing the EEC was to be able to
obtain peer review of any proposed design changes
and solicit agreement from the sponsoring organi-
zations for implementation of these changes.
While the T1DGC infrastructure was established
to collect ASPs, flexibility to accommodate design
changes was built in, to the extent possible. This
was especially true with respect to the language of
study materials provided to the IRBs. The approval
for recruitment of trios and case–control collections
added complexity to the study. New data collection
forms had to be designed and additional training
had to be initiated. However, most IRBs considered
the addition of new cohorts as a modification of the
approved protocol and provided expedited review.
Although the T1DGC established four regional
networks, the designation of networks was arbitrary
(to some extent) and resulted from early participa-
tion of investigators from those regions in the
planning of the project. Unfortunately, T1DGC
could not accommodate investigators in regions or
countries who wanted to have their own network.
Each regional Network in turn designated a set of
network laboratories. T1DGC insisted on rigorous
QA procedures and was able to achieve and
maintain quality performance across the different
network laboratories. Investigators from some
countries declined to participate in T1DGC,
arguing that they had laboratories and technologies
in their own countries and refusing to send samples
to a central location. Finally, it was a condition for
funding that samples collected for T1DGC must be
exported and deposited in the NIDDK Central
Repositories. These conditions prevented certain
countries (e.g., China, Japan and Korea) from
participating. Recruitment for a future worldwide
genetics project might take these limitations into
account and begin with pilot collections in several
nations to increase confidence and accommodate
differences.
As a genetics study (and not, for example, a
clinical trial), T1DGC planned no sustained contact
with the participants. In some networks, no re-
contact was explicitly stated in the consent form.
As data on T1DGC participants accumulates, it
would have been useful to be able to re-contact
participants for collection of additional samples to
carry out functional studies.
Conclusions and recommendations
The T1DGC is a NIDDK- and JDRF-sponsored
project whose primary aims are to: (a) discover
genes that modify risk of type 1 diabetes and (b)
expand upon existing genetic resources for type 1
diabetes research. T1DGC set an ambitious recruit-
ment target of 2500 ASP families worldwide and
established the organization and infrastructure that
completed this recruitment and also collected
additional trios, cases, and controls.
T1DGC’s four regional Networks (Asia-Pacific,
European, North American, and United Kingdom)
were responsible for coordinating recruitment
activities within each region, but were given the
flexibility to develop that region as deemed neces-
sary for the overall success of the Consortium. This
flexibility meant that each network could deal
sensitively with the particular social, cultural,
ethical, and legal issues of their different countries.
Standardized data collection was an overarching
goal of the T1DGC – even with worldwide
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T1DGC Coordinating Center monitored and sup-
ported the activities within the four Network
Centers. The protocol, manual of operations, and
forms were developed centrally at the Coordinating
Center, with input from network representatives.
The Coordinating Center developed QA procedures
and implemented quality monitoring for all net-
works, including the network laboratories. Good
communication and expedient problem solving are
key requirements for success.
The T1DGC data and sample collection
includes ASP families, trios, cases, and controls.
Results of genetic analyses have identified many
novel new regions that affect susceptibility to type
1 diabetes [24–30]. T1DGC data and samples are
accessible to the research community and should
prove to be particularly rich resources well into the
future.
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Appendix 1
Type 1 Diabetes Genetics Consortium Agreement
Background
The international Type 1 Diabetes Genetics
Consortium (T1DGC) is a collaborative group
formed to facilitate the genetic analysis of type 1
diabetes (T1D) via the sharing of reagents, meth-
ods, strategies, samples, knowledge, and data at all
levels of the research effort, from individual groups
to existing and future collaborative networks. The
T1DGC will help both researchers and funding
agencies monitor progress, and formulate, plan,
and assess the most informative and cost-effective
strategies. It will help motivate researchers, peer
reviewers, and lay people to push forward the
identification of genes and mechanisms in T1D. It
will encourage sample and data sharing while
maintaining the environment for new initiatives,
both small and large, across the wide spectrum of
approaches and technologies required in genetic
analysis of complex diseases.
This initiative is undertaken in order to
help increase consensus in the field, to provide
an opportunity to collate data from a variety of
studies for combined analyses and to increase
clarity for future initiatives. A major role for the
T1DGC will be to act as a repository for data and
samples, to support scientists worldwide and to
encourage new ideas for research in Type 1
diabetes.
Activities of the Consortium
T1DGC has the following activities:
1) The Consortium will provide an integrated map
and new analysis of the combined data set of
affected sibling pair (ASP) families (n 1200).
The combined data set includes genome-scan
data from a combined US–UK collection (AJHG
2001, 69:820-830), and from a Scandinavian
collection (AJHG 2001, 69:1301-1313). This
analysis is ongoing. The data will be made
available to all investigators on request when
the manuscript has been accepted.
2) The Consortium will transmit samples from
approximately 600 ASP families already col-
lected by various investigators to the Center
for Inherited Disease Research (CIDR) for whole-
genome scan analysis. This submission has
already occurred.
3) The Consortium will organize and collect an
additional 2500 ASP families throughout the
world. In order to conduct this recruitment, the
Consortium has been organized into regional
Networks. These families will provide DNA,
plasma and serum samples, and phenotypic
and medical history information. Family mem-
bers will also be asked to allow immortalized cell
lines to be made. A whole genome-scan analysis
will be conducted on the DNA from recruited
families. All samples (DNA, plasma, serum, cell
lines) will eventually be deposited in a central
NIDDK repository and be made available to the
scientific community.
4) The Consortium has received funding to iden-
tify genes under the five most promising linkage
peaks identified by the analysis. The Steering
Committee will develop specific procedures for
this identification.
5) Such procedures in the future could include
association studies and genetic analyses of
diverse ethnic groups, using trios, cases, and
controls.
Steering Committee of T1DGC
The T1DGC will be guided by a Steering Committee
(SC), the membership of which is as follows:
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Beena Akolkar NIDDK Bethesda, MD USA
Pat Concannon University of
Virginia
Charlottesville,
VA
USA
Henry Erlich Roche Molecular
Systems/CHORI
Oakland, CA USA
Cecile Julier Centre National
de Genotypage
Paris France
Grant
Morahan
Western
Australian
Institute for
Medical Research
Perth Australia
Jorn Nerup Hagedorn
Research
Institute
Gentofte Denmark
Flemming
Pociot
Hagedorn
Research
Institute
Gentofte Denmark
Stephen Rich
(Chair)
University of
Virginia
Charlottesville,
VA
USA
John Todd University of
Cambridge
Cambridge UK
Under the terms of funding, the NIDDK Program
Officer is a full member of the SC.
Decisions are made by the Steering Committee
by majority vote of a quorum of its membership.
SC Voting Members are: Akolkar, Concannon,
Erlich, Julier, Morahan, Nerup, Pociot, Rich, and
Todd. Seven SC members constitute a quorum
empowered to conduct T1DGC business. A simple
majority vote (4/7 or 5/8 or 5/9) is considered
binding.
TheSChasestablishedseveralcommitteestohelp
with the functioning of the Consortium. These
committees are: Access; Bioinformatics; Ethical,
Legal, and Social Implications (ELSI); Molecular
Technology; Phenotyping/Recruitment; Publica-
tions and Presentations; and Quality Control.
The Coordinating Center for T1DGC has been
established at Wake Forest University.
The T1DGC has funding from the NIDDK (NIH)
and the Juvenile Diabetes Research Foundation
(JDRF) to initiate a worldwide collection of affected
sibling pair (and other pedigree types) families for
on-going linkage studies and future association
studies.
Network Organization
The T1DGC framework will support and foster
Regional Networks. The Network PIs, working with
physicians in local clinics, will be responsible for
recruiting T1D subjects and families and for
upholding local ethical conditions, informed con-
sent, and compliance.
The Regional Networks and PIs are:
Network PI Institution Country
Asia-Pacific Peter Colman Walter & Eliza Hall
Institute
Australia
Grant Morahan
European Jorn Nerup Hagedorn Research
Institute
Denmark
Flemming Pociot Hagedorn Research
Institute
Denmark
North
American
Carla Greenbaum Benaroya Research
Institute
USA
United
Kingdom
John Todd University of
Cambridge
UK
Network investigators will be subject to national
and regional laws and regulations in force.
This includes appropriate ethical review and
approval. Study subjects will have the right to
request that their samples and information be
destroyed at any time in the future. The details of
the procedure for this request will be determined by
Network policy.
Consortium Member Rights and Responsibilities
Investigators who choose to participate in the
Consortium agree to abide by the following
principles:
1) Each participating group will indicate their
willingness to participate in the consortium
effort and to abide by the principles outlined
in this Consortium Agreement by providing a
signed copy of this Consortium Agreement. By
signing this Agreement, the investigator will
receive Member access to the T1DGC website
(http://www.t1dgc.org).
2) There are several ways to participate in the
Consortium. These include:
– participating in the recruitment of new col-
lections for and on behalf of the Consortium,
using Consortium resources
– providing genotyping or other research
resources to the Consortium
– participating in the activities of Consortium
committees
– participating in the analysis of aggregate
Consortium data
3) Some investigators have provided previously
collected samples for submission to CIDR, as
indicated in activity 2, above. In this case, the
contributing investigator has agreed:
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derived from the analysis of the samples they
contributed to the Consortium, including
HLA, INS, and CTLA4 typing and genome
scan data;
– to retain the right to analyze and publish their
own data, with no non-scientific restrictions
on timing or content;
– to retain any intellectual property rights
deriving from their separate analysis and/or
publication of their own data;
– to participate in any joint analyses conducted
by the Consortium, and to keep any interim
results of such analyses confidential;
– to be recognized in publications to be co-
authored by ‘The Type 1 Diabetes Genetics
Consortium’.
4) An investigator may choose to participate in the
Consortium by helping to recruit families for
the Consortium collection indicated as activity
3, above. A group that contributes to the
recruitment of new collections for and on
behalf of the Consortium agrees to the
following:
– to participate in the discussions leading to the
establishment of Consortium standards for
collection, and to abide by those standards;
– to obtain signed informed consent from
volunteers according to high ethical and
legal standards;
– to provide the Consortium-determined quan-
tities of blood, serum, plasma, and other
samples, and to send these biological samples
to Consortium-designated laboratories;
– to obtain phenotype and medical history
information from volunteers, and to report
this information to a Consortium-designated
Center;
– to inform the Consortium if there are any
ancillary studies being conducted while
recruiting for the Consortium. An investigator
agrees to provide the set of data and samples
required by the Consortium.
– Laboratory results may be returned to the
investigator, depending on Network policy. It
is up to the discretion of the investigator to
share this information with the subject,
according to individual data collection site
requirements. It is the responsibility of the
Network to develop any statements about the
interpretation of data, and to request that this
statement be shared with participants.
– In the case where site requirements mean no
laboratory results will be returned to the
subject, and the subject makes an explicit
request for this information, a second sample
will be sent to another laboratory designated
by the subject. The subject will pay for this
testing and results.
– Investigators must agree to destroy any sam-
ples and information when subjects have
requested withdrawal from the study.
Investigators must notify their regional
Network of any request for destruction of
samples and information. The details of the
procedure for this request will be determined
by Network policy.
5) A group that contributes to recruitment for and
on behalf of the Consortium has the following
rights:
– The Consortium is committed to providing
data to contributors. It is the responsibility
of the contributing investigator to obtain
the appropriate ethical and privacy board
review and approvals for receiving coded
data and materials from the Consortium.
Contributors may be required to provide
these assurances prior to data and/or materials
release.
– Contributors will receive access to data
derived from the analysis of the samples
they contributed to the Consortium, includ-
ing HLA, INS, and CTLA4 typing and genome
scan data. For NIH purposes, the T1DGC
Coordinating Center (CC) must track who
requests data and where it goes. Therefore, all
investigators have to make written requests
for data; email is acceptable. Contributors can
request immediate access to the genome scan
data for their own analysis, and the CC will
provide that data as soon as the data are
received.
– Contributing investigators have the right to
receive DNA and/or immortalized cell line
aliquots of samples they contributed to the
Consortium.
– Contributing investigators retain the right to
analyze and publish their own data, with no
non-scientific restrictions on timing or
content.
– Contributors retain any intellectual property
rights deriving from their separate analysis of
and/or publication of their own data.
– Contributors have the right to participate in
any joint analyses including the data from
their samples conducted by the Consortium,
and agree to keep any interim results of such
analyses confidential.
– Contributors agree to acknowledge the
Consortium in publications and
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mined by the Consortium Publications and
Presentations Committee.
– Contributors will be recognized in publica-
tions to be co-authored by ‘The Type 1
Diabetes Genetics Consortium’.
– Contributors will be eligible to apply for
access to Consortium resources for additional
analyses, according to policies and timetables
established by the Consortium Steering
Committee.
Consortium Responsibilities
1) The Consortium agrees to the following:
– to establish mechanisms for interested groups
to participate in the activities of the
Consortium;
– on request, to return the results of analysis of
samples provided by contributing
investigators;
– on request, to provide an aliquot of DNA
and/or immortalized cell lines made from
samples provided by contributors;
– on request, to notify the NIDDK Central
Repository of any request to destroy contrib-
uted samples and information;
– to recognize the right of contributors to
analyze and publish their own data, with no
non-scientific restrictions on timing or
content;
– to establish mechanisms for contributors to
participate in any joint analyses including the
data from their samples conducted by the
Consortium;
– to recognize the contributing groups and
individuals in publications to be co-
authored by ‘The Type 1 Diabetes Genetics
Consortium’.
2) The Consortium will transmit collected DNA
samples to the Center for Inherited Disease
Research (CIDR) for whole-genome scan analy-
sis. Because the samples will be assembled from
a worldwide recruitment, the Consortium
expects samples to be ready in a staggered
schedule. Approximately 800 families will be
provided in each of three submissions to CIDR.
Each Network will have samples in each sub-
mission to CIDR.
An anticipated schedule for submissions to
CIDR, receipt of data from CIDR and data releases
is according to the following approximate
timetable:
Submission to
CIDR
Data received
from CIDR
Expected release
of aggregate
data analysis*
January 2003 October 2003 þ6 months
December 2004 August 2005 þ6 months
December 2005 August 2006 þ6 months
December 2006 August 2007 þ6 months
*The Consortium expects to release the results of the aggregate
analysis incorporating the samples from each submission
according to the approximate schedule above.
On request from contributing investigators, the
Consortium will provide whole-genome scan data
on the contributed samples as soon as it is received.
The Consortium will undertake quality control
analysis of the data and will also begin linkage
analysis on the aggregate data. Linkage analysis will
be done only on the aggregate data set, and
according to policies determined by the Steering
Committee. Contributors have the right to partici-
pate in any joint analyses that includes data from
their samples that are conducted by the
Consortium. Contributors agree to keep any
interim results of such analyses confidential.
The Consortium will release the genotypic data
to Consortium Members from each submission 6
months after receipt of the data from CIDR.
At the conclusion of the study, the Consortium
will create a database for the NIDDK Central
Repository, according to the requirements of the
Repository. Access to Consortium data will then be
governed by policies determined by the NIDDK
Central Repository.
The Consortium has no expectation that paten-
table information or material will result from the
combined or aggregate Consortium database, and
the Consortium will not assert or claim any such
intellectual property (IP) rights. It may be possible
for individual investigators who follow up the
linkage results to generate patentable information
or material, but they will need to decide themselves
whether to claim any such potential intellectual
property.
3) The Consortium agrees to provide resources
for genetic analyses to the scientific community.
The Consortium has received funding to
identify genes under the five most promising
linkage peaks identified by the analysis. The
Steering Committee will develop specific
procedures for this identification. For additional
research in the genetics of type 1 diabetes,
the following working model is being
developed:
(a) Investigators interested in identifying genes
may apply for access to Consortium samples.
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Review Group (IRG) acting according to poli-
cies drawn up by the Access Committee, and
ratified by the Steering Committee.
(c) The IRG would include ad hoc reviewers,
outside scientists (with expertise not in dia-
betes), and representatives of the funding
agencies.
(d) Multiple applications may result in recommen-
dation that collaborations be implemented.
This would ensure that high-cost, labor-inten-
sive positional cloning would be done with
minimum overlap among labs.
(e) IP issues would be negotiated between or
among investigators working on a particular
region.
(f) When publication is in press, the data would
be provided to the Consortium. The
Consortium would make the data available
after publication. All the data will become
known and available to the scientific
community.
(g) Investigators who receive samples and
information provided by the Consortium
must agree to destroy those samples and
information when notified by the T1DGC
Coordinating Center or by the NIDDK Central
Repository.
(h) The Consortium would be recognized in pub-
lications in the author line, footnote, or
acknowledgement, according to policies devel-
oped by the Publications and Presentations
Committee. These issues could be sorted out
during the review of the application.
4) Samples provided to the Consortium will, at
least initially, be deposited in a regional
Network repository. Regional Network reposi-
tories will initially store samples of DNA, cell
lines, plasma, and serum. At timed intervals,
and according to a schedule agreed by the
Steering Committee and NIDDK, regional
Network repositories will ship DNA, cell lines,
plasma, and serum samples to the NIDDK
Central Repository.
All samples (DNA, plasma, serum, cell lines) will
eventually be deposited in the NIDDK Central
Repository. These samples will be made available
to the scientific community according to policies
and a timetable to be determined by the Steering
Committee and agreed with NIDDK. Contributing
investigators will have an opportunity to provide
input as these policies are developed. At the
conclusion of the study, access to T1DGC materials
will be governed by policies determined by the
NIDDK Central Repository.
Study subjects will have the right to request that
their samples and information are destroyed at any
time in the future. The details of the procedure for
this request will be determined by Network policy.
The general outline is as follows: the T1DGC Coor-
dinating Center at Wake Forest University will be
responsible for notifying the NIDDK Central Repo-
sitorytodestroyrequestedsamplesandinformation.
Attheendofthestudy,eachregionalNetworkwillbe
responsible for notifying the NIDDK Central Repo-
sitory to destroy samples and information, when
subjects request withdrawal from the study.
Investigators who receive samples and informa-
tion provided by T1DGC must agree to destroy
those samples and information when subjects
request withdrawal from the study and upon
notification by the T1DGC Coordinating Center
or NIDDK Central Repository.
The Consortium will not commercialize the
DNA or data deposited with the Consortium. No
individual or group will own or claim intellectual
property rights to the combined or aggregate
Consortium database, other than copyright or
similar rights to control use and access to the
database or the publication of information and
findings generated by the Consortium.
5) The Steering Committee will examine educa-
tional and other activities as part of its commit-
ment to establish mechanisms for all interested
groups to participate in the activities of the
Consortium.
6) The Steering Committee will establish proce-
dures to evaluate opportunities to extend the
results of research to develop methods of risk
prediction, prevention and therapy in type 1
diabetes. All interested investigators will have an
opportunity to provide input as these proce-
dures are developed.
Consortium Agreement
I have read the provisions of this Consortium
Agreement, and Iagree to beboundby its principles.
——————————————————————
Investigator Name
——————————————————————
Investigator Signature
——————————————————————
Date
——————————————————————
Network PI Signature
——————————————————————
Date
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Type 1 Diabetes Genetics Consortium Policy
Governing Access to Study Repository Samples and
Data
This Access Policy applies to T1DGC Contributing
Investigators and Consortium Members until the
end of the T1DGC study (NIH#U01DK062418). At
that time, requests for access to T1DGC samples
and data will be governed by policies determined
by the NIDDK Central Repository, as specified in
the T1DGC Consortium Agreement. All requests
from non-members are governed by NIDDK Central
Repository policies.
  The study database is frozen on a quarterly basis
(January 1, April 1, July 1, and October 1);
cumulative data sets can be requested following
each freeze, as outlined in this policy and
according to the timetable below.
  Samples can be requested by T1DGC investiga-
tors twice a year (January–February and July–
August).
TIMETABLE:
Samples and data may be requested (for each participant
provided) by Contributing Investigators.
6 months later !
Access to samples/data may be requested by T1DGC
members.
12 months later !
Access to samples/data may be requested by non-members.
Access Investigator Categories
The T1DGC recognizes two groups of investigators:
T1DGC members, who have submitted a signed
Consortium Agreement to one of the T1DGC
Network Centers or the Coordinating Center
(including both T1DGC Contributing
Investigators and T1DGC investigators who do
not contribute samples) and non-members, who
have not submitted a Consortium Agreement.
  All T1DGC member requests for access to
samples or data (excluding requests for partici-
pants provided by Contributing Investigators)
will be handled by the T1DGC Access
Committee.
  All non-member requests for access to samples or
data will be handled by application to the NIDDK
Central Repository.
  Preference for access to T1DGC holdings is
accorded to T1DGC members. T1DGC members
may request access to T1DGC samples and data
12 months before non-members may submit
similar requests.
  T1DGC members will receive preferential receipt
of samples and data.
  The T1DGC website will be used to notify
investigators of samples and data available for
access applications.
Contributing Investigators. Investigators who have
contributed samples to T1DGC have the right to
request data and samples for each participant
provided.
  Requests for quarterly data freezes may be
submitted to the investigator’s Regional
Network Center at any time.
  Requests for samples may be submitted to the
investigator’s Regional Network Center in
January–February and July–August.
  Procedures detailed in the ‘Contributing
Investigator Request for Samples and
Data,’ section of the T1DGC website must be
followed.
  Contributing Investigators have priority access to
data and samples for each participant they
provide. T1DGC will bear the cost for transferring
samples to Contributing Investigators.
  Contributing Investigators will have priority
receipt of samples and data.
Non-contributing Investigators (T1DGC Members).
T1DGC members may request access to data and
samples on individuals they did not contribute to
the T1DGC six months after these become available
to the Contributing Investigator.
Investigators Not Members of the T1DGC (Non-
Members). Investigators who are not members
of the T1DGC may request access to data and
samples (through an application to the NIDDK
Central Repository) 12 months after these become
available to T1DGC members, or 18 months after
these become available to the Contributing
Investigator.
Renewable and Non-Renewable Resources
There are two types of Consortium resources:
renewable and non-renewable. Data and DNA
aliquots obtained from cell lines are considered
renewable resources. Whole-genome amplified DNA,
plasma, and serum are considered non-renewable
resources.
Data. Data, referring to information obtained or
generated as a result of Consortium activities, are
T1DGC design and implementation S21
http://ctj.sagepub.com Clinical Trials 2010; 7: S5–S32considered a renewable resource. Examples of such
data include medical information (e.g., age-at-
onset), immunological information (i.e., IA2,
GAD65 autoantibodies), and genetic information
(e.g., genome scan linkage data, HLA genotype data,
INS, CTLA4). T1DGC databases include results from
T1DGC-directed genetic analyses, laboratory assays
of serum and plasma specimens, and data collected
on T1DGC forms.
Samples. Samples, referring to biological materials
obtained from blood, include cell lines, genomic
DNA, whole genome amplified DNA, plasma, and
serum.
  Only Contributing Investigators are entitled to
receive a cell line aliquot from samples that they
submit, and only for use that is consistent with
any restrictions arising from informed consent.
Cell lines will not otherwise be distributed by the
T1DGC.
  There are different criteria for access to renewable
versus non-renewable samples. There are also
different review and approval procedures (see
below).
  Because access depends on sample availability,
requests for access to samples may be made only
according to a determined schedule. This applies
to both renewable and non-renewable sample
resources.
  Access to each sample will be governed by the
provisions of its associated informed consent
form. This means that some samples may be
restricted to non-commercial use. Ordinarily,
investigators who receive access to samples will
also receive access to the data associated with
those samples. However, data may become avail-
able to the investigator on a different time
schedule than the samples.
  The timing of release of non-renewable sample
resources is likely to be different from the timing
of release of renewable samples.
  The investigator who receives access to T1DGC
samples will bear the costs for sample transfer.
Applying for Access to Renewable and Non-Renewable
Resources
To apply for access to T1DGC samples and/or data,
complete the Access Application form posted in the
‘Application for Access to T1DGC Data and
Sample,’ section of the T1DGC website. NOTE:
The Access Application form is Appendix 2.A of this
document (.pdf version) and is also posted on the
T1DGC website (.doc version).
Applications must be submitted to the Access
Committee via the web-based Access System. A
Confidentiality Certification (Appendix 2.B) for all
individuals with access to the data or samples
should be completed and submitted to the Regional
Network Center or Coordinating Center (for
T1DGC members).
The timetable for applying for access to
specified T1DGC resources depends on T1DGC
membership (see TIMETABLE above and/or the
T1DGC website).
General Guidelines
  All applications will be reviewed by the Access
Committee for concordance with the aims of the
T1DGC and security.
  The Coordinating Center will keep confidential
records of all applications and will provide the
Steering Committee regular summary reports of
its activities. For non-renewable applications, the
evaluation forms from each Access Member
and the written critique from the Access
Committee Chair will be the sole record of the
deliberations.
  Access is conditional on availability of
samples and/or data, and agreement to abide by
T1DGC policies related to publication,
specimen disposal, custodianship, ethical
approval and informed consent, patenting, and
confidentiality.
  Access to each sample will be governed by the
provisions of its associated informed consent
form. Access to samples from particular countries
is subject to the laws pertaining to those
countries; individuals requesting access to sam-
ples will be required to sign an agreement
acknowledging that they understand and will
comply with any country-specific restrictions
associated with certain samples. A plan for
compliance will be required for the application
requesting access to restricted samples.
  Access to T1DGC samples and/or data is condi-
tional on the investigator agreeing to submit
results to the NIDDK Central Repository for
incorporation among the T1DGC data holdings,
which enhances the scientific value of
these samples and extends opportunities for
collaborative research. This reporting must
occur within one year after receipt of the samples
and/or data.
  The Access Request system will simultaneously
notify the Coordinating Center of all successful
applications so that it can begin the process of
data and/or sample transfer. Transfer will be
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sample collection and storage. Transfer of
required data from the T1DGC database will be
negotiated directly with the applicants. The
Coordinating Center will regularly report to the
Access Committee on the status of sample and
data transfers.
  Unsuccessful applicants may revise their applica-
tion and re-apply to the Access Committee. If the
application is denied a second time, the unsuc-
cessful applicant may appeal the decision. An
appeal will be considered only if the review
process was flawed. The Chair of the Steering
Committee will determine if the review was
flawed and, if so, the Steering Committee will
constitute a separate review group to handle the
appeal and review the application.
  The T1DGC Publications and Presentations
Committee will track publications derived from
T1DGC samples and data. Investigators granted
access to samples and data will be requested to
provide updated information on such publica-
tions to that Committee. Study publications
policy (set by the T1DGC Publications and
Presentations Committee) will govern the cita-
tion and release of this information to the
general public.
  The T1DGC Coordinating Center maintains
summary reports of its databases on the pass-
word-protected study website. These include,
in aggregate, distributions of genetic and pheno-
typic characteristics of the study cohort and
data related to the collection and processing of
these samples. The nature and content of these
reports are determined by T1DGC committees,
its sponsors, and its External Evaluation
Committee.
Approval Process for Renewable Resources
For renewable sample resources, the main criterion
for approval of applications is scientific
appropriateness.
  Applications for renewable samples will be
considered approved if approved by majority
vote of six members of the Access Committee.
Applications will be decided within four weeks of
receipt. The Access Committee Chair will notify
applicants of the final decision.
  Approval for access to subsequent versions of the
T1DGC database may be requested through an
extension of the original access request.
Extension of a data request is permissible only
if the specific aims of the original request have
not changed since the time of the initial
submission. If the specific aims have changed, a
new access request must be submitted.
Approval Process for Non-Renewable Resources
For non-renewable sample resources, the main
criterion for approval of applications is scientific
merit; additional criteria considered by the Access
Committee are outlined below.
1) The Access Committee (which includes a repre-
sentative from the Coordinating Center and the
funding agencies) will review each application
for access to non-renewable samples, using the
form developed for this purpose (Appendix 2.C).
In addition, one outside reviewer will be
appointed by the Chair of the Access
Committee. A primary reviewer will be
appointed in each review panel, using the NIH
model. The T1DGC Coordinating Center
representative will be responsible for evaluating
the logistical needs of the application and
confirming the availability of the requested
samples.
2) Factors considered in the review of applications
for non-renewable specimens include the scien-
tific merit of the application, its uniqueness and
potential contribution, synergy with the goals of
the T1DGC, and the research experience of the
applicant. Overlapping applications may result
in recommendation that collaborations be
implemented.
3) Applications for non-renewable resources
should:
  clearly state the hypothesis to be tested and the
number of samples needed to achieve this (i.e.,
power calculations);
  state precisely what assays will be undertaken, by
what methods and the amount of sample
required for each;
  contain an undertaking not to use the sample
for any other purpose without prior
authorization;
  include an undertaking to return all unused
sample by a given deadline; and
  explain why T1DGC samples are needed (i.e.,
why no other resources can address the
hypothesis).
4) Applications for non-renewable samples will be
considered approved if approved by a two-thirds
majority of the Access Committee (including
the external reviewer). Applications will be
decided within 12 weeks of receipt. The review
panel will develop a written critique of each
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Access Committee Chair will notify applicants
of the final decision.
Appendix 2.A
T1DGC Application for Access to Data and Samples
Date of submission:
Resource Requested: (Mark all that apply.)
Renewable Resources:
« DNA (5mcg aliquot)
« Data (Specify requested data)
set[s]: _______________________________________
NOTE: Data set name is a required field. See list of
‘‘Available Data Sets and Samples’’ under ‘‘Access to
T1DGC Data and Samples’’ link on www.t1dgc.org.
Non-Renewable Resources:
« Whole Genome Amplified DNA (5mcg aliquot)
« Serum (0.5mL aliquot)
« Plasma (0.5mL aliquot)
Project title:
Corresponding investigator and full contact informa-
tion:
Name:
Address:
Telephone:
FAX:
E-mail:
Name(s), affiliation(s) and address(es) of major co-
investigator(s) and/or collaborator(s):
Name(s), affiliation(s) and address(es) of project
analyst(s):
Abstract (250 words or less):
Specific aims:
Previous peer review of the project. Indicate whether the
genetic components of the project have undergone
previous peer review, and by whom. Indicate the outcome
of the review. If an application is currently pending at the
NIH, provide details about the study section and institute
assignment, if known.
Source(s) of funds for the project. If no new funds are
required, this should be stated. If funded by the NIH, list
the sponsoring institute and the dates of support. If
approval is sought conditional on the applicant’s success
in obtaining funding, a specific timeline for this must be
provided.
Number of samples to be analyzed and the projected
timeline for obtaining the samples from T1DGC. (For
non-renewable resources, a formal justification for the
requested number of samples must be provided, including
power analyses. This is critical for access to the limited
plasma and serum samples.)
Brief outline of the plan for the next phase of the
project if linkage or association is found (if applicable).
Include specific plans for isolating the locus (loci) and
name the individuals responsible for each step. Attach
letters of collaboration from these individuals.
Description of core data required from the T1DGC
central databases, including process and phenotypic
data.
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T1DGC Confidentiality Certification
All individuals with any access to Type 1 Diabetes
Genetics Consortium (T1DGC) data must sign a
Confidentiality Certification. This includes, but is
not limited to, the following groups of individuals:
  Principal Investigators
  Co-Investigators and Investigators
  CoordinatingCenterstaff,includinganydataentry,
data management, data analysis and support staff
  Regional Network staff and support staff
Measures to ensure the security of specimens and data.
In addition, plans for disposal of any unused specimens
and data must be described.
Background information about the disease/trait
including the rationale for carrying out this particular
study. Describe any unique features about the disease/
trait that would single out this project for special
consideration.
Analysis strategy for the resulting information and
choice of analytic methods and software. If collabora-
tions are established for analytical services, include letters
of collaboration.
Assurance that the project has been reviewed
for human subject protection by an appropriate
Institutional Review Board (IRB) or Ethics Committee
(EC).
Description of any commercial aims and likely benefits
ensuing from the project. Details of pending or
granted patents relevant to the application must be
provided.
If samples are requested, please provide shipping
contact information.
Name of Contact:
Shipping Address:
E-mail Address:
Phone Number:
Have all of co-investigators and collaborators approved
the final version of this application? « YES « NO
Is there a deadline for submission of this material to an
external agency? « YES « NO
If yes, what is the deadline and when would you like
comments back?
__________/__________/___________
DD/MM/YYYY
I have read and agree to abide by the T1DGC Access
Policy, the T1DGC Publications and Presentations
Policy, and the consent guidelines conferred by study
participants.
« YES « NO
I have signed and submitted the T1DGC
Confidentiality Certification to the Network Center
or the Coordinating Center.
« YES « NO
All individuals who will have access to the data and/or
samples have submitted the T1DGC Confidentiality
Certification to the Network Center or the
Coordinating Center.
« YES « NO
I agree to submit all results from analysis of these
samples to the NIDDK Central Repository for incor-
poration among the T1DGC data holdings (including
information on quality control methods).
« YES « NO
I understand that some samples will be restricted to
non-commercial use only.
« YES « NO
Applications for non-renewable resources must include
submission of the following items:
  CV(s) for key personnel involved in the project (NIH
format required)
  Letter(s) of support/commitment from major colla-
borator(s) and/or co-investigator(s)
  Essential reprints or preprints (no more than 3)
Submission of these items is optional for applications
for renewable resources.
T1DGC design and implementation S25
http://ctj.sagepub.com Clinical Trials 2010; 7: S5–S32  Field Center staff and support staff
  Laboratory staff and support staff
  Data analysts (on-site and off-site)
  Fellows and students
  Consultants
  Ancillary study investigators
Each individual with access to T1DGC data must
read, sign, and date the Confidentiality
Certification. The Network Principal Investigator
must also sign the certification and keep the
original copy on file at the Regional Network
Center. A copy of the completed certification
should be forwarded to the Coordinating Center.
The Principal Investigators (Field Centers,
Regional Networks, and Coordinating Center) are
responsible for ensuring that all individuals cur-
rently affiliated with the T1DGC Study through
their site sign the Confidentiality Certification. The
Coordinating Center is specifically responsible for
ensuring that all subcontractors and consultants to
the Study through the Coordinating Center con-
tract, including laboratory investigators and staff,
sign the Confidentiality Certification. The Principal
Investigators are responsible for ensuring that all
individuals who become affiliated with the T1DGC
Study through employment or consulting in the
future sign the Confidentiality Certification at the
time he/she joins the Study.
Type 1 Diabetes Genetics Consortium
Confidentiality Certification
As an employee of, consultant to, or fellow/student
involved with the Type 1 Diabetes Genetics
Consortium (T1DGC) Study funded by the
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), I am aware of the
confidential nature of data on research participants
maintained by the Study, and the necessity of
maintaining that confidentiality.
I agreenot totransferor disclose any confidential
data, nor any information about individual T1DGC
Studyparticipants,exceptasnecessaryfordata/safety
monitoring or programmatic management, in the
course of my responsibilities at work nor in private,
either during or after my affiliation with the T1DGC
Study. I agree not to transfer any T1DGC data or
biological specimens to individuals outside the
T1DGC Study Group without the written permission
oftheT1DGCSteeringCommittee.Further,Iagreeto
returnallT1DGCdatatothePrincipalInvestigatoror
delete/destroy all T1DGC data upon termination of
my affiliation with the Study.
I understand that as an employee of, consultant
to, or fellow/student involved with the T1DGC
study, I am subject to the provisions of laws and
regulations related to confidentiality of study data
in the country where the work is performed.
Name (print): __________________________________
Signature: ______________________________________
Date: __________________________________________
T1DGC Site: ____________________________________
Principal Investigator’s Signature: ________________
Date: __________________________________________
Appendix 2.C
T1DGC Evaluation Form: Non-Renewable
Resource Request
Access Request Number: AR
Please rate items 1–5 as ‘‘Acceptable’’ or
‘‘Not Acceptable’’. All comments will be for-
warded to the investigator submitting the
request.
1) Importance of the scientific question to type 1
diabetes research:
Acceptable _________ Not Acceptable _________
Comments:
2) Unique requirement for samples requested:
Acceptable __________ Not Acceptable _________
Comments:
3) Quality and thoroughness of the proposal in
outlining the specific hypotheses and methods:
Acceptable _________ Not Acceptable _________
Comments:
4) Number of samples and amount of sample
required:
Acceptable __________ Not Acceptable _________
Comments:
5) Plan for sharing data results with other
investigators:
Acceptable _________ Not Acceptable _________
Comments:
6) Additional comments or questions:
———————————————————————–
Request Approved: __________
Request Not Approved: ___________
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Type 1 Diabetes Genetics Consortium
Asia-Pacific Network: Tracey Baskerville (Mater
Children’s Hospital, Australia); Nines Bautista
(Institute for Study on Diabetes Foundation,
Philippines); Eesh Bhatia (Sanjay Gandhi
Postgraduate Institute, India); Vijayalakshmi
Bhatia (Sanjay Gandhi Postgraduate Institute,
India); Kamaruzaman Bin Hasan (National
University of Malaysia Hospital, Malaysia);
Francois Bonnici (University of Cape Town, South
Africa); Thomas Brodnicki (Walter & Eliza Hall
Institute of Medical Research, Australia); Brian
Browning (The University of Auckland, New
Zealand); Fergus Cameron (Royal Children’s
Hospital, Australia); Katharee Chaichanwatanakul
(Mahidol University, Thailand); Pik To Cheung
(Queen Mary Hospital, Hong Kong); Peter
Colman
2,5,11,15 (Walter & Eliza Hall Institute of
Medical Research, Australia); Andrew Cotterill
(Mater Children’s Hospital, Australia); Jenny
Couper (Women’s and Children’s Hospital,
Australia); Patricia Crock (John Hunter Children’s
Hospital, Australia); Ric Cutfield (North Shore
Hospital, New Zealand); Tim Davis (Fremantle
Hospital, Australia); Paul Dixon (Diabetes Lifestyle
Centre, New Zealand); Kim Donaghue (Children’s
Hospital at Westmead, Australia); Katrina Dowling
4
(Australian Red Cross Blood Service, Australia); Paul
Drury (Auckland Diabetes Centre, New Zealand);
Sarah Dye (Western Australia Institute for Medical
Research, Australia); Shane Gellert
2 (The Royal
Melbourne Hospital, Australia); Rohana Abdul
Ghani (National University of Malaysia Hospital,
Malaysia); Ristan Greer (University of Queensland,
Australia); Xueyao Han (Peking University People’s
Hospital, China); Len Harrison (Walter & Eliza Hall
Institute of Medical Research, Australia); Nick
Homatopoulos
4 (Australian Red Cross Blood
Service, Australia); Linong Ji (Peking University
People’s Hospital, China); Tim Jones (Princess
Margaret Hospital for Children, Australia); Loke
Kah Yin (Children’s Medical Institute, Singapore);
Nor Azmi Kamaruddin (National University of
Malaysia Hospital, Malaysia); Uma Kanga (All
India Institute of Medical Sciences, India); Alok
Kanungo (Cuttack Diabetes Research Foundation,
India); Gurvinder Kaur (All India Institute of
Medical Sciences, India); Betty Kek (Children’s
Medical Institute, Singapore); Simon Knowles
4
(Australian Red Cross Blood Service, Australia);
Jeremy Krebs (The Diabetes Centre, New Zealand);
Neeraj Kumar (All India Institute of Medical
Sciences, India); Yann-Jinn Lee
7 (Mackay
Memorial Hospital, Taiwan); Xiaoying Li
(Shanghai Jiao-Tong University, China);
Supawadee Liktimaskul (Mahidol University,
Thailand); Margaret Lloyd (Children’s Hospital at
Westmead, Australia); Amanda Loth
5,10 (Walter &
Eliza Hall Institute of Medical Research, Australia);
Anthony Louey
3,4 (Australian Red Cross Blood
Service, Australia); Narinder Mehra
8 (All India
Institute of Medical Sciences, India); Tony
Merriman (University of Otago, New Zealand); Liu
Min (Beijing Children’s Hospital, China); Grant
Morahan
1,9,12,14,15 (Western Australia Institute for
Medical Research, Australia); Robert Moses
(Illawarra Diabetes Services, Australia); Grant
Mraz
4 (Australian Red Cross Blood Service,
Australia); Rinki Murphy (Auckland Diabetes
Centre, New Zealand); Ian Nicholson
4 (Australian
Red Cross Blood Service, Australia); Araceli Panelo
(Institute for Studies on Diabetes Foundation,
Philippines); Perlita Poh
2 (Royal Melbourne
Hospital, Australia); Gareth Price (Mater Medical
Research Institute, Australia); Nirubasini Ratnam
(Princess Margaret Hospital for Children, Australia);
Carani Sanjeevi
6 (Karolinska Hospital, Sweden);
Saikiran Sedimbi (Karolinska Hospital, Sweden);
Shuixian Shen (Fudan University, China); Goh
Siok Ying (The Children’s Medical Institute,
Singapore); Brian Tait
3,4,5,6 (Australian Red Cross
Blood Service, Australia); Nikhil Tandon (All India
Institute of Medical Sciences, India); Allison
Thomas (Walter & Eliza Hall Institute of Medical
Research, Australia); Mike Varney
3,4 (Australian Red
Cross Blood Service, Australia); Praewvarin
Weerakulwattana (Mahidol University, Thailand);
Jinny Willis (Christchurch Hospital, New Zealand.
European Network: Elvis Abang Akwo (Yaounde
Central Hospital, Cameroon); Lotte Albret
5,10
(Hagedorn Research Institute and Steno Diabetes
Center, Denmark); Francisco Ampudia-Blasco
(Clinic University Hospital Valencia, Spain); Jesus
Argente (Hospital Infantil Universitario Nino Jesus,
Spain); Magdalena Avbelj (University Children’s
Hospital, Slovenia); Gulja Babadjanova (Moscow
State Medical University, Russia); Klaus
Badenhoop
14 (University Clinic Frankfurt/Main,
Germany); Tadej Battelino (University Children’s
Hospital, Slovenia); Georg Beilhack
14 (University of
Ulm, Germany); Regine Bergholdt (Hagedorn
Research Institute and Steno Diabetes Center,
Denmark); Polly Bingley
2,5 (University of Bristol,
United Kingdom); Bernhard Boehm
4,5,14 (Ulm
University, Germany); Jo Bolidson
2 (University of
Bristol, United Kingdom); Kerstin Brismar
(Karolinska Hospital, Sweden); Caroline Brorsson
14
(Hagedorn Research Institute and Steno Diabetes
Center, Denmark); Joyce Carlson
3,5 (University
Hospital MAS, Sweden); Luis Castano (Hospital de
Cruces, Spain); Kyla Chandler
2 (University of
Bristol, United Kingdom); Valentino Cherubini
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University Hospital, Czech Republic); Elisa
Cipponeri (University Campus Bio-Medico, Italy);
Raquel Corripio Collado (Consorci Sanitari Parc
Tauli, Spain); Alberto de Leiva (Hospital Sant Pau,
Spain); Iveta Dzivite (University Children’s
Hospital, Latvia); Ana Fagulha (University
Hospital, Portugal); Merce Fernandez Balcells
(Hospital Trueta, Spain); Beatriz Garcia Cuartero
(Hospital Severo Ochoa, Spain); Concepcion Garcia
Lacalle (Hospital Severo Ochoa, Spain); Cristian
Guja (Institute of Diabetes, Nutrition & Metabolic
Diseases, Romania); Pilar Gutie ´rrez (Hospital
Universitario de Getafe, Spain); Alona Hamou
(Schneider Children’s Medical Center of Israel,
Israel); Erifili Hatziagelaki (University of Athens,
Greece); Simon Heath
7 (Centre National de
Genotypage, France); Kaire Heilman (Tartu
University Children’s Hospital, Estonia); Wolfgang
Helmberg
5,7 (Medical University Graz, Austria);
Orna Hermon (Schneider Children’s Medical
Center of Israel, Israel); Marta Hernandez
(Hospital Universitari Arnau de Vilanova and
Hospital Universitario de Canarias, Spain); Iris
Holzheu
4 (Ulm University, Germany); Nora
Hosszufalusi (Semmelweis University, Hungary);
Jorma Ilonen (University of Turku, Finland);
Constantin Ionescu-Tirgoviste (Institute of
Diabetes, Romania); Jesper Johannesen (Steno
Diabetes Center, Denmark); Cecile Julier
1,9,12,14
(Centre National de Genotypage, France);
Heinrich Kahles
14 (Klinikum der J.W. Goethe-
Universita ¨t, Germany); Ida Kinalska (Medical
University of Bialystok, Poland); Mikael Knip
(University of Helsinki, Finland); Ingrid
Kockum
7,14 (Karolinska Hospital, Sweden); Eija
Kojo (University of Helsinki, Finland); Olga
Kordonouri (Children’s Hospital auf der Bult,
Germany); Adam Kretowski (Medical University of
Bialystok, Poland); Dora Krikovszky (Semmelweis
University, Hungary); Angelika Kurkhaus
4 (Ulm
University, Germany); Madiusz Kuzmicki (Medical
University of Bialystok, Poland); Eva Lavant
3
(University Hospital MAS, Sweden); Anna Long
2
(University of Bristol, United Kingdom); Johnny
Ludvigsson (University Hospital, Sweden); Laszlo
Madacsy (Semmelweis University, Hungary);
Katarzyna Maliszewska (Medical University of
Bialystok, Poland); Mara Marga (P. Stradins
University Hospital, Latvia); Marissa Penna
Martinez (University Clinic Frankfurt/Main,
Germany); Didac Mauricio
6 (Hospital Universitari
Arnau de Vilanova and Hospital Sant Pau, Spain);
Gertrud Mazurkievicz
4 (Ulm University, Germany);
Jorn Nerup
1,15 (Steno Diabetes Center, Denmark);
Antanas Norkus (Institute of Endocrinology of
Kaunas University of Medicine, Lithuania);
Francisco Javier Novoa Mogollon (Hospital
Universitario Insular, Spain); Anna Okruszko
(Medical University of Bialystok, Poland); Chiara
Pettinari (Salesi Hospital, Italy); Moshe Phillip
(Schneider Children’s Medical Center of Israel,
Israel); Valdis Pirags (P. Stradins University
Hospital, Latvia); Flemming Pociot
1,11,12,14,15
(Hagedorn Research Institute and Steno Diabetes
Center, Denmark); Paolo Pozzilli (University
Campus Bio-Medico, Italy); Radu Racasan
(University Clinic Frankfurt/Main, Germany);
Klemens Raile (Vircow Clinic Charite ´ Berlin,
Germany); Rebecca Rappner
3 (University Hospital
MAS, Sweden); Maria Jesus Rodriguez Troyano
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